This year, the number of influenza vaccine production and batch issuance in China has increased significantly compared with previous years. However, in terms of the quantity balance between different regions, it is necessary to strengthen the scheduling < / P > < p > it will take 2-4 weeks after vaccination to produce antibodies with protective level. In order to ensure that the recipients can get immune protection before the epidemic season, it is suggested that the public should do their best after the local influenza vaccine is put on the market Rapid vaccination < / P > < p > from November to march of the next year is the high incidence period of influenza. Recently, influenza vaccination has been carried out in many regions of China, including Beijing, Zhejiang and Gansu. Novel coronavirus pneumonia, influenza vaccine, should we fight? Is there enough capacity? How to fill the gap of vaccination? With these high public concerns about the issue of influenza vaccine in autumn and winter, Newsweek interviewed industry insiders in many ways. On September 29, the comprehensive group of joint prevention and control mechanism of the State Council issued the 2020 edition of. This is the third year in a row that China has released a national influenza prevention and control program. It is suggested that influenza vaccination is an effective means to prevent and control influenza worldwide. Influenza is an acute respiratory infectious disease, fever and systemic symptoms are more obvious, seriously endangering people’s health. Influenza virus is easy to mutate, and outbreaks can occur in places where people gather in schools, nurseries and nursing homes. Influenza causes 3-5 million severe cases and 290000-650000 respiratory disease-related deaths worldwide every year. Pregnant women, infants, the elderly and patients with chronic underlying diseases and other high-risk groups have a higher risk of serious disease and death after influenza. And because influenza virus is easy to mutate, the immunity of vaccination will gradually weaken over time, so influenza vaccine needs to be vaccinated every year. At present, influenza vaccination has been carried out in many regions of the country. It is understood that the first round of 60000 influenza vaccines dispatched in Gansu Province was completed at the end of August; elderly people with household registration of over 70 years old in Zhejiang Province are registered for vaccination appointment; Beijing started vaccination in stages and batches in late September; and community vaccination clinics in Shanghai have also started appointment vaccination of influenza vaccine. Novel coronavirus pneumonia is not necessary. Only
, who is the director of the first hospital of Jilin University, Bethune, said that influenza vaccination is necessary. Only when the flu is controlled, there are not many people who have a fever or respiratory symptoms, can they identify the patients with new crown pneumonia more quickly and accurately, and at the same time, reduce the pressure of nucleic acid detection of the new crown virus. < p > < p > a special note recently issued by the China Center for Disease Control and prevention: this year, the severe epidemic situation of the new global epidemic will continue. Influenza vaccination is the most effective means to prevent influenza. It can not only significantly reduce the risk of influenza and serious complications, but also reduce the harm of influenza related diseases and the occupation of medical resources. In general, it takes 2-4 weeks after vaccination to produce antibodies with protective level. In order to ensure that recipients can get immune protection before influenza season, it is suggested that the public should be vaccinated as soon as possible after the local influenza vaccine is launched.
is affected by novel coronavirus pneumonia this year. People’s willingness to vaccinate influenza is generally enhanced and vaccine sales have increased substantially. Can vaccine supply meet the needs of the public? From the perspective of vaccine sources, the World Health Organization (who) predicts the influenza situation every year and releases the strains of influenza vaccine, and the enterprises organize the production according to the strains of that year. Compared with previous years, three of the four major influenza strains in the northern hemisphere published by who have mutated, and enterprises need to produce new vaccines based on these mutated strains. After interviewing several vaccine manufacturers, the reporter learned that under the epidemic situation, the time when the enterprises received the virus strains and standard samples was affected to some extent. In addition, the production cycle of influenza vaccine is long, which requires high stability of technology and technology. Zhang Heping, general manager of Sanofi Pasteur China, a flu vaccine manufacturer, said that to complete the production of an influenza vaccine, it would take a total of 6 stages and 22 steps, of which 70% were used for quality control. Each batch number had more than 100 detection points and more than 400 test parameters, and the conventional production cycle required 6-7 months. < / P > < p > despite these adverse conditions, the supply of influenza vaccine in China this year is still significantly increased compared with that in 2018 and 2019. < / P > < p > according to the website of the State Food and Drug Administration and the vaccine batch issuance information, there are 9 manufacturers supplying influenza vaccine in 2020-2021. It is estimated by the industry that the planned production of influenza vaccine in China will reach 50 million copies in 2020. According to the relevant person in charge of the State Food and drug administration, measures have been taken to meet the supply of influenza vaccine this year, and the number of vaccine production and batch issuance has increased significantly compared with previous years. However, in terms of the quantity balance between different regions, the scheduling needs to be strengthened. The next batch issuance quantity will be timely adjusted according to the incidence, demand and contract between disease control and vaccine manufacturers On the basis of ensuring the quality and safety of the products, we should ensure that the vaccine manufacturers can fully prepare the products and make plans and preparations in advance.
novel coronavirus pneumonia, Yu Qingming, Secretary of the national drug group of Cmi Holdings Ltd, a leading pharmaceutical company in China, told reporters that this year’s new pneumonia epidemic has caused widespread increase in people’s willingness to vaccinate influenza and the sales of vaccines have increased substantially. At present, Changchun biology, Shanghai biology and other enterprises affiliated to Sinopharm group have produced about 7 million doses of influenza vaccine. In order to avoid the shortage of “one vaccine is difficult to obtain”, the enterprises are stepping up the workshop transformation and expanding production capacity. Wu Liangyou, deputy director of the disease control bureau of the National Health Commission, said at a news conference that this year, the National Health Commission has asked all localities to set up more vaccination sites, start vaccination appointment ahead of time, extend vaccination cycle, and increase daily service time to ensure more convenient service for the masses. According to the experts interviewed, there is still room for improvement in the coverage rate of influenza vaccine in China. Feng Luzhao, executive vice president of the school of medicine and public health of the Chinese Academy of Medical Sciences and Peking Union Medical College, said that the annual influenza vaccination rate in China is between 2% and 3%, and it is expected to reach 4% this year, but this is still insufficient for the protection of the whole population. Experts suggest that the coverage of influenza vaccine should be expanded in autumn and winter, and relevant production capacity plans should be made to ensure supply. In the long run, China should also increase efforts to promote the exploration of new technical routes of influenza vaccine and improve the flexibility of production cycle. < / P > < p > first of all, we should do a good job of vaccine deployment balance and short-term capacity replenishment plan among regions. The interviewees suggested that the relevant departments of the state could establish and improve the dialogue platform between supply and demand of influenza vaccine, establish a linkage mechanism between supply and demand, so that enterprises can prepare production plans in advance, and “placing orders in advance” is an effective means to ensure supply. “The United Kingdom, the United States, Germany, France and other countries have established a pre ordering system to order the vaccine needed for the next influenza season 7 to 10 months in advance.” A person in charge of a vaccine manufacturer said. < / P > < p > Second, we should improve the domestic influenza vaccination plan. Experts suggest that we should promote free vaccination in high-risk areas and high-risk populations, give priority to all kinds of key groups as stipulated in the guidelines of the China Center for Disease Control and prevention. < / P > < p > Third, to promote the exploration of new technical routes of influenza vaccine. Zhang Heping suggested that the state should encourage innovation and speed up the introduction of foreign advanced influenza vaccines. He said that in addition to the traditional preparation technology based on chicken embryo culture, there is also a genetically modified influenza vaccine which has been put on the market in foreign countries. The production of this product does not depend on the number of eggs without specific pathogen, and the production cycle is short. It can not only reduce the time pressure of annual influenza vaccine production, but also make emergency preparation for the prevention of global influenza outbreak, which can be considered. Waistcoat line type abdominal abuse posture, shaping the perfect abdominal curve!